Revenue Trends Bio Reference Laboratory has recently seen diagnostic revenue fluctuations with a notable Q2 decrease to 74.5M from prior-year levels around 101.1M, suggesting an opportunity to discuss efficiency, pricing, and service line optimization to stabilize and grow diagnostic revenue.

Strategic divestiture The March 2025 asset sale of BioReference Health’s laboratory testing businesses to LabCorp indicates a shift in strategic focus and potential for partnership or cross-sell opportunities in core clinical testing and oncology-related services within New York and New Jersey.

Geographic Focus Core operations and revenue emphasis are concentrated in New York and New Jersey, presenting a targeted selling area for lab services, genomic testing programs, and clinical trial collaborations with regional health systems and research institutions.

Genomics & Trials Recent launches and partnerships in genomic testing and clinical research portfolios signal openness to expanding genomic diagnostics, pharmacogenomics, and trial support services to life sciences firms and hospital networks.

Partnership Potential Historical collaborations and partnerships with care networks (example with Junction) and oncology testing initiatives suggest ongoing receptivity to co-marketing, referral arrangements, and integrated lab service solutions with health systems and specialty clinics.